UNASSIGNED: A 37-year-old woman presented to the nephrology department with a 6-year history of MCD. The diagnosis of MCD was confirmed via renal biopsy. She initially achieved CR with steroid treatment but experienced relapse during steroid tapering. Subsequent CR was achieved with a regimen of steroids and tacrolimus although multiple relapses occurred. Rituximab led to another CR, but its maintenance lasted only 6 months. The response to subsequent rituximab treatments was unsatisfactory. Ultimately, obinutuzumab was selected, resulting in the induction and maintenance of CR for 12 months.
UNASSIGNED: This case demonstrates the successful treatment of frequently relapsed, steroid-dependent, and rituximab-resistant MCD with obinutuzumab. Obinutuzumab is a promising therapeutic option for rituximab-resistant MCD.
■一位37岁的女性出现在肾脏病科,有6年的MCD病史。通过肾活检证实了MCD的诊断。她最初通过类固醇治疗获得CR,但在类固醇逐渐减少期间经历了复发。尽管发生了多次复发,但使用类固醇和他克莫司的方案实现了随后的CR。利妥昔单抗导致另一个CR,但它的维护只持续了6个月。对随后的利妥昔单抗治疗的反应不令人满意。最终,选择了obinutuzumab,导致CR的诱导和维持12个月。
■此病例证明了对频繁复发的成功治疗,类固醇依赖性,和利妥昔单抗耐药的MCD与奥比妥珠单抗。奥比妥珠单抗是利妥昔单抗耐药MCD的一种有前途的治疗选择。